Last update 22 Dec 2024

Bexarotene

Last update 22 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid, Bexarotene (JAN/USAN/INN)

+ [21]

Target

RXRs

Mechanism

RXRs agonists(Retinoid X receptor agonists), Protein synthesis inhibitors

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

Cutaneous T-Cell LymphomaCushing SyndromeEsophageal Squamous Cell Carcinoma+ [2]

Inactive Indication

Advanced breast cancerAdvanced Lung AdenocarcinomaAdvanced Lung Non-Small Cell Carcinoma+ [8]

Originator Organization

Ligand Pharmaceuticals, Inc.

Active Organization

Eisai GmbHBausch Health Ireland Ltd.

Weill Medical College of Cornell University

+ [5]

Inactive Organization

Ligand Pharmaceuticals, Inc.

Eisai, Inc.

Drug Highest PhaseApproved

First Approval Date

US (29 Dec 1999),

Cutaneous T-Cell Lymphoma

RegulationOrphan Drug (JP), Orphan Drug (US)

Structure

Molecular FormulaC24H28O2

InChIKeyNAVMQTYZDKMPEU-UHFFFAOYSA-N

CAS Registry153559-49-0

Clinical Trials associated with Bexarotene

NCT05296304 / RecruitingPhase 1IIT

A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF).
Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin.
The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

Start Date16 Mar 2022

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

NCT04664829 / RecruitingPhase 1IIT

Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype

Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance.
Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour.
The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.

Start Date01 Oct 2020

Sponsor / Collaborator

National Cancer Centre of Singapore Pte Ltd.

ACTRN12620000825954 / CompletedPhase 1

A single dose, randomized, blinded, pharmacokinetic study of a generic formulation of 75 mg 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2- naphthalenyl) ethenyl] benzoic acid capsule in a 2 way crossover comparison against the innovator 75 mg 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2- naphthalenyl) ethenyl] benzoic acid capsule conducted under fed conditions in healthy volunteers.

Start Date21 Aug 2020

Sponsor / Collaborator

Zenith Technology Corp. Ltd.

100 Clinical Results associated with Bexarotene

100 Translational Medicine associated with Bexarotene

100 Patents (Medical) associated with Bexarotene

1,047

Literatures (Medical) associated with Bexarotene

01 Feb 2025·COMPUTATIONAL BIOLOGY AND CHEMISTRY

A structure-based approach to discover a potential isomerase Pin1 inhibitor for cancer therapy using computational simulation and biological studies

Article

Author: Song, Jiawen ; Jiang, GuoZhen ; Wang, Wang ; Jiang, Qizhou ; Zhang, Zhenxian ; Liu, GuoPing ; lv, Shaoli ; Xie, Chao ; Zou, Yanling ; Zhang, Yuxi ; Qiu, Binxuan ; Lv, Shaoli ; Hu, Qingyang ; Tao, Jiaxin ; Li, Jiaqi ; Zhong, Hui

Peptidyl-prolyl cis/trans isomerase Pin1 occupies a prominent role in preventing the development of certain malignant tumors. Pin1 is considered a target for the treatment of related malignant tumors, so the identification of novel Pin1 inhibitors is particularly urgent. In this study, we preliminarily predicted eight candidates from FDA-approved drug database as the potential Pin1 inhibitors through virtual screening combined with empirical screening. Therefore, we selected these eight candidates and tested their binding affinity and inhibitory activity against Pin1 using fluorescence titration and PPIase activity assays, respectively. Subsequently, we found that four FDA-approved drugs showed good binding affinities and inhibition effects. In addition, we also observed that bexarotene can reduce cell viability in a dose-dependent and time-dependent manner and induce apoptosis. Finally, we inferred that residues K63, R68 and R69 are important in the binding process between bexarotene and Pin1. All in all, repurposing of FDA-approved drugs to inhibit Pin1 may provide a promising insight into the identification and development of new treatments for certain malignant tumors.

01 Jan 2025·BIOCHEMICAL PHARMACOLOGY

The LDL Receptor-Related Protein 1: Mechanisms and roles in promoting Aβ efflux transporter in Alzheimer’s disease

Review

Author: Chen, Jixiang ; Xu, Bo ; Zhou, Jiecan ; Yang, Mingxia ; Li, Weiyi ; Chen, Canyu ; Gao, Lili

The LDL Receptor-Related Protein 1(LRP1), a member of the Low-density Lipoprotein (LDL) receptor family, is a multifunctional cellular transporter and signaling receptor, this includes regulation of lipid metabolism, cell migration and signaling. Abnormal accumulation of amyloid beta (Aβ) in the brain is thought to be the main pathological change in Alzheimer's disease. By binding to a variety of ligands, LRP1 is involved in the internalization and degradation of Aβ, thereby affecting the course of Alzheimer's disease (AD). Here, we discuss the main mechanisms by which LRP1 mediates Aβ degradation and clearance and several current therapeutic approaches targeting LRP1. Finally, we concluded that modulating the expression level of LRP1 is an effective way to attenuate Aβ deposition and ameliorate AD. Abbreviations: LRP1, LDL Receptor-Related Protein 1;LDL, Low Density Lipoprotein; Aβ, amyloid beta; AD, Alzheimer's disease; APP, amyloid precursor protein; ApoE, apolipoprotein E; TGF, growth factor; MMP, matrix metalloproteinase;TAT, thrombin-antithrombin complex; BBB, blood-brain barrier; MMP-9,cyclophilin A (CypA)-matrix metalloproteinase-9; VMC, Vascular Mural Cell; IDE,insulin degrading enzyme; EVs, extracellular vesicles; sLRP1,shed LRP1; BDNF, brain-derived neurotrophin; IGF-1,insulin-like growth factor 1; NGF, nerve growth factor; MAPK,mitogen-activated protein kinase; ERK1/2,exogenous signal-regulated kinase1/2;JNK, c-Jun amino-terminal kinase; TLR4, toll-like receptor 4; NF-κB,nuclear factor-κB; GCAP,guanylate cyclase-activating protein; KD, ketogenic diet;KB, ketone body; BLECs,Brain-like endothelial cell; BYHWD, Buyang Huanwu decoction; LGZG, Linguizhugan decoction;P- gp, P-glycoprotein;PPARγ, Peroxisome proliferator-activated receptor γ;SP16,SERPIN peptide 16; Asx, Astaxanthin; Bex, Bexarotene.

01 Dec 2024·Recent patents on anti-cancer drug discovery

Integrating Bioinformatics and Drug Sensitivity Analyses to Identify Molecular Characteristics Associated with Targeting Necroptosis in Breast Cancer and their Clinical Prognostic Significance

Article

Author: Liu, Guowen ; Zheng, Chang ; Guo, Hanbin ; Mo, Yongpan

Background::

Breast cancer accounts for over 1.8 million new cases worldwide annually, and prompt diagnosis and treatment are imperative to prevent mortality. Necroptosis, a form of programmed cell death, is thought to be a critical pathway for cancer cell apoptosis, yet, its relationship with breast cancer progression and molecular mechanisms remains largely unexplored.

Objectives::

Our study aims to investigate the molecular characteristics and clinical prognostic value of necroptosis-related genes in breast cancer using a comprehensive approach that involves integrated bioinformatics analysis along with drug sensitivity assessment.

Methods::

Transcriptional, clinical, and tumor mutation burden (TMB) data related to breast cancer from the TCGA and GEO databases were integrated, and the necroptosis gene set was downloaded from the GSEA website for analysis. The screening conditions were set as adjusted p < 0.05 and |log2FC(fold change)| > 0.585 to screen for differential expression genes related to breast cancer necroptosis. Survival prognosis analysis was conducted on breast cancer necroptosis genes. Further analysis was conducted on prognosis-related necroptosis genes, including immune infiltration analysis and GO/KEGG enrichment analysis, to explore the potential biological functions and signaling pathway mechanisms of breast cancer necroptosis genes. Drug sensitivity screening was conducted on the prognosis-related necroptosis to identify potential drugs that target the promotion of necroptosis gene expression, and ultimately, single-gene analysis was performed on the core target genes obtained.

Results::

Through integrated bioinformatics analysis, 29 differentially expressed mRNAs related to BRCA-Necroptosis were identified, including 18 upregulated mRNAs and 11 downregulated mRNAs. In addition, single-factor analysis of differential genes showed that the expression of HSPA4, PLK1, TNFRSF1B, FLT3, and LEF1 was closely related to BRCA survival prognosis. Based on the expression of these genes, a breast cancer prognosis model was constructed, and it was found that the area under the curve (AUC) of the curve of the risk genes for necroptosis was the largest, indicating that these genes have a certain clinical predictive significance for the occurrence and prognosis of BRCA. Additionally, there were significant differences in clinical characteristics of BRCA patients with different necroptosis gene expressions. Furthermore, GSVA and immune infiltration analysis revealed that Necroptosis-DEGs mainly affect the occurrence and progression of BRCA by participating in immune functions such as APC co-inhibition, APC co-stimulation, CCR, checkpoint, as well as infiltrating immune cells such as B cells naive, plasma cells, and T cells CD8. Moreover, the necroptosis gene group column chart indicated a 1-year survival rate of 0.979, a 3-year survival rate of 0.883, and a 5-year survival rate of 0.774. The necroptosis gene group and column chart are important indicators for evaluating BRCA prognosis. Finally, drug sensitivity screening of BRCA-Necroptosis genes showed that compounds such as A-770041, AC220, AP-24534, Bexarotene, and BMS-509744 have certain effects as potential targeted drugs for the treatment of BRCA necroptosis genes.

Conclusion::

Necroptosis genes are implicated in the pathogenesis and progression of breast cancer and are thought to impact the prognosis and response to drug treatments in individuals with BRCA. Consequently, understanding the role of these genes in breast cancer may aid in identifying more precise and efficacious therapeutic targets.

News (Medical) associated with Bexarotene

31 Jul 2024

·www.fiercehealthcare.com

Wells Fargo relationship with Express Scripts under scrutiny in new lawsuit

Wells Fargo joins Johnson & Johnson as the most recent company sued over employee prescription drug price management. Wells Fargo is the most recent corporation to get sued, as alleged by former employees, for inadequately overseeing the price workers were forced to pay for prescription drug prices.In a class action lawsuit filed in federal court named Navarro et al v. Wells Fargo Company, employees say the company did not fulfill its fiduciary obligations. Under the Employee Retirement Income Security Act of 1974, employers are required to adequately manage employee benefits programs.The plaintiffs argue Wells Fargo’s management of the prescription drugs program resulted in higher premiums, out-of-pocket costs and limited wage growth because of the prices it agreed to pay Express Scripts, one of its pharmacy benefit managers, for generic drugs.Employees, they say in the suit, were forced to pay nearly $10,000 for a a prescription of fingolimod, used to treat multiple sclerosis, when the generic version could be purchased without insurance for less than a $1,000 at pharmacies like Cost Plus Drugs and Rite Aid. “No prudent fiduciary would agree to make its plan and participants/beneficiaries pay a price that is fifteen times higher than the price available to anyone who just walks into a pharmacy and pays without using their insurance,” the plaintiffs said in the lawsuit.Across approximately 300 generic drugs, Wells Fargo and Express Scripts made employees pay a markup on average of 114.97% what it costs pharmacies to obtain the drugs, the lawsuit alleges. For specialty drugs, employees said they paid a markup of 383% on average.Other prescriptions were far more expensive for employees at Express Scripts’ pharmacy Accredo. Bexarotene gel, available at Rite Aid for $3,750, cost employees nearly $70,000 from Accredo.“The price discrepancies noted herein are illustrative of a pervasive and systematic problem of unreasonable prescription drug charges, despite well-known alternatives available to defendants,” the lawsuit said. Plaintiffs in the lawsuit say Wells Fargo should have received better rates from Express Scripts or a different PBM, guided employees to more cost-effective options or utilized a pass-through PBM that doesn’t use spread pricing.Wells Fargo was also tagged with accusations that it should have operated with more expertise given its standing in the industry. Plaintiffs noted Wells Fargo publishes research on the economics of the pharma industry, hosts an annual healthcare conference with speakers from major PBMs, operates an employee benefits consulting practice and has publicly warned about rising prescription drug costs and business practices by Express Scripts.A similar lawsuit was filed against Johnson & Johnson in February by the same law firm, Fairmark Partners.“This case alleges that Wells Fargo has failed its employees once again, this time by agreeing to obviously unreasonable terms and prices with its PBM that cause workers to vastly overpay for prescription drugs,” said Michael Lieberman, an attorney with Fairmark Partners. “After years of scrutiny and with clear alternatives available, there are no excuses left for a large corporation like Wells Fargo to ignore its legal obligation to identify reasonable prescription drug coverage options for its employees.” Mark Cuban, founder of Cost Plus Drugs, said in a X post that this type of lawsuit can be expected to occur more often.“This lawsuit is going to happen over and over and over with self insured companies until they realize they have to drop their big 3 PBM and use a Pass Through PBM,” he said. “The good news is if they switch they will save money and get control of their claims data.”As well as the Wells Fargo health plan, top human resource employees were also named as defendants in the lawsuit.Wells Fargo and Express Scripts did not immediately respond to a request for comment from Fierce Healthcare.Aon, the broker for Wells Fargo, was also listed in the lawsuit. Express Scripts was not listed as a defendant.

Patent Infringement

26 Oct 2023

·www.prnewswire.com

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies. The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community. Continue Reading SciTech Medical Advisory Board "SciTech is excited and incredibly proud that this world-class group of medical experts will assist us with innovative insights that enable us to bring ST-001 to patients who have limited options in their cancer treatments," said President and Managing Partner Earle Holsapple. "The clarity they bring in understanding the clinical needs of patients will serve to guide us through the commencement of our phase 1 clinical trial and through our subsequent expedited clinical program." The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D. Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity." Dr. Duvic is a Professor of Medicine and Dermatology practices in Houston, Texas, and holds the Blanche Bender Endowed Chair of Research. Her clinical research includes translational/molecular studies leading to improved therapies for cutaneous T-cell lymphomas. She has written over 500 peer-reviewed papers and a book on Retinoids. She participated in the development of topical and oral tazarotene and bexarotene which both received FDA approval. Larisa J. Geskin, MD, FAAD - "I am thrilled to support SciTech's innovative approach to cancer therapeutics. SciTech's patented nanoparticle platform, SDP, enhances the effectiveness and safety of fenretinide, which has shown promise in treating patients with incurable cutaneous lymphomas in preliminary studies. SciTech's flagship product, ST-001, stands out for its ability to deliver therapeutic doses without toxic side effects, greatly benefiting our patients." Dr. Geskin is a Professor of Dermatology (in Medicine, Division of Hematology-Oncology) at Columbia University Medical Center and the Director of the Comprehensive Cutaneous Oncology Center at the Columbia University Department of Dermatology. Dr. Geskin serves as the Immediate Past-President of the International Society for Cutaneous Lymphomas (ISCL), the Secretary-Treasurer of the US Cutaneous Lymphomas Consortium (USCLC), and the Founding Chair of the New York Cutaneous Lymphoma Consortium (NYCLC), among her many other responsibilities. Ajay K. Gopal, MD - "Based on the encouraging preclinical data from a variety of laboratories, our observed tolerability of fenretinide, and the unmet need in a spectrum of malignancies novel formulations such as ST-001 nanoFenretinide are certainly worthy of further investigation." Dr. Gopal received his undergraduate degree from Duke University and his MD from Emory University. He completed his internal medicine training at Duke University School of Medicine and his oncology training at the University of Washington and Fred Hutchinson Cancer Center, where he currently holds an endowed chair and serves as a Professor and Clinical Research Director for Hematologic Malignancies. Dr. Gopal has over 2 decades of experience in the development of novel therapies for lymphoma, as reflected by over 200 publications in the field, including the first translational and clinical trial data evaluating fenretinide in lymphoma. Contact: Earle Holsapple Email: [email protected] About SciTech Development SciTech Development, LLC is a clinical-stage pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines SDP and the drug fenretinide as a new drug product with potentially broad effectiveness in many cancers. For more information about the Company, please visit: SOURCE SciTech Development

Phase 1Executive Change

17 Nov 2022

·medcitynews.com

Two Pharmacy Owners Plead Guilty in $18M Foreign Medicare Fraud Scheme

Two New York pharmacy owners who “exploited the Covid-19 emergency for their own financial gain,” pleaded guilty to an international scheme to submit fraudulent claims to Medicare for cancer medication, the Department of Justice announced Wednesday. Arkadiy Khaimov, 39, of Forest Hills, and Peter Khaim, 42, also of Forest Hills, engaged in an elaborate healthcare scheme involving more than a dozen pharmacies in New York, according to the justice department. The two would submit millions of dollars in fraudulent Medicare claims for expensive cancer drugs that were not prescribed or distributed to patients. The drugs, Targretin gel, made by Bausch and Panretin gel, made by Concordia, were allegedly dispensed during periods when certain pharmacies were closed due to the pandemic. “Khaim, Khaimov, and their co-conspirators exploited the Covid-19 emergency for their own financial gain by using COVID-19-related ‘emergency override’ billing codes to submit additional fraudulent claims for Targretin Gel 1%,” the justice department said in a news release. The scheme started in New York but became a complex international endeavor as the two men attempted to launder money, amounting to more than $18 million. Khaim and Khaimov established shell companies and sham pharmacy wholesale companies to create the illusion they were operating actual businesses. In reality, they were sending funds from the false Medicare claims to the sham companies. Then, the funds were sent to companies in China and distributed to individuals in Uzbekistan. At that point, the two men received some of the funds in cash, the announcement said. They also allegedly sent money from the fraudulent claims to their relatives through cashier’s checks and used the money themselves to purchase property. Both men face a 20-year prison sentence and their separate hearings are scheduled for May 2023. A spokeperson for the Center for Medicare and Medicaid Services did not immediately respond to a request for comment.

Patent Infringement

100 Deals associated with Bexarotene

External Link

KEGG	Wiki	ATC	Drug Bank
D03106	Bexarotene	L01XX25	DB00307

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cutaneous T-Cell Lymphoma	US	Valeant Pharmaceuticals Luxembourg SARL	29 Dec 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia Areata	Phase 3	US	Ligand Pharmaceuticals, Inc.	01 May 2003
metastatic non-small cell lung cancer	Phase 3	US	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	AT	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	CA	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	FR	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	DE	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	ES	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	US	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	AT	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	CA	Eisai, Inc.	01 May 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FRI511 (ENDO2023)	Not Applicable	Hypothyroidism	-	Bexarotene	zourgecttl(yadqpcjcxt) = mzuhtyfdgx zhdprtidvv (sycmtxmjfy, 0.8 - 1.7) View more	-	05 Oct 2023
TCL-213 (SOHO2023)	Not Applicable	Peripheral T-Cell Lymphoma	-	Bexarotene 150 mg/m^2	nscdicyzqo(qytyfbkide) = The most common toxicities were hypothyroidism and hyperlipidemia and effectively managed tavqidgucc (acbqzvxecl ) View more	Positive	01 Sep 2023
NCT03323658 (CTgov)	Phase 1	Atypical Lobular Breast Hyperplasia \| Noninfiltrating Intraductal Carcinoma \| Invasive Mammary Carcinoma	24	Bexarotene (Dose Level 1)	ffwwrqpwdn(zxghqtldyo) = xitwbfxgue ycombbpsie (ajaklitoeg, gatshbyomv - itheqmhqrk) View more	-	06 Dec 2022
NCT03323658 (CTgov)	Phase 1		24	Bexarotene (Dose Level 2)	ffwwrqpwdn(zxghqtldyo) = dzxqnxdtxz ycombbpsie (ajaklitoeg, ihwvkejvdk - stbswojzas) View more	-	06 Dec 2022
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	-	31	Bexarotene	xmkxkfodtu(gntzjnuqqi) = significant adverse events were observed on the trial eqfsarvyne (kvvhaigtxn )	Positive	12 Oct 2021
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Bexarotene	tiquhmuwig(zudqvrqxwb) = jkhjizqmpu gnbwgepnlz (ddesileyiz ) View more	-	12 Oct 2021
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Placebo	tiquhmuwig(zudqvrqxwb) = iwlrijqdyp gnbwgepnlz (ddesileyiz ) View more	-	12 Oct 2021
CCMR-One (ECTRIMS2020)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Bexarotene 300mg/m2	topdmgdjbs(mcfcfpgggf) = 100% of bexarotene patients experienced central hypothyroidism jpfuzticiu (ajhetbjora ) View more	Positive	07 Dec 2020
CCMR-One (ECTRIMS2020)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Placebo		Positive	07 Dec 2020
NCT00615784 (UPCC04407, CTgov)	Phase 2	Acute Myeloid Leukemia	24	Bexarotene	yipneyqtkr(tmhqjobras) = coafkzqvrj zqghzslamu (pbnjtydoya, pqjehsmlds - dexuflvsvt) View more	-	17 Nov 2020
NCT01007448 (CTgov)	Phase 4	CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma	59	Bexarotene	mmqeiqvnza(vcvoybbiyf) = miepiceuol bagronkhmj (kkvoqskqpg, vouqhhucve - idyfvwjhop) View more	-	12 Nov 2019
NCT00153842 (CTgov)	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma \| Advanced Lung Adenocarcinoma	33	Carboplatin+Bexarotene+Paclitaxel (Phase IB: Bexarotene 300mg, Paclitaxel and Carboplatin)	inzpdsaayw(pmdhjmxjdz) = rigvsifggu msavtdxgzf (pewdatplfb, nxqqzthcbl - fqxbeszojv)	-	06 Mar 2019
NCT00153842 (CTgov)	Phase 1/2		33	Carboplatin+Bexarotene+Paclitaxel (Phase IB: Bexarotene 400mg, Paclitaxel and Carboplatin)	inzpdsaayw(pmdhjmxjdz) = mdsiigbqlw msavtdxgzf (pewdatplfb, qneqqmjwrg - cynjmmhruy)	-	06 Mar 2019
NCT00125359 (CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	42	Erlotinib+Bexarotene	viaxldtmus(heyrekicmt) = rueeoadypc epmpntlkul (gcrnxcitut, rzhpwcwytv - tjrjyjptmt) View more	-	13 Nov 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis